Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A proof of concept study of RVT-104

Trial Profile

A proof of concept study of RVT-104

Phase of Trial: Phase I

Latest Information Update: 21 Jun 2017

At a glance

  • Drugs RVT 104 (Primary)
  • Indications Alzheimer's disease; Lewy body disease
  • Focus Adverse reactions; Proof of concept
  • Most Recent Events

    • 21 Jun 2017 New trial record
    • 13 Jun 2017 According to an Axovant Sciences media release, this trial is planned to initiate in second half of 2017 based on data from RVT-103 proof of concept study (see profile 276007).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top